Orexo AB has announced promising in vivo proof-of-concept data for a powder-based intranasal vaccine candidate based on Abera Bioscience AB’s BERA vaccine platform and formulated with Orexo’s Amorphox technology.
Lyme disease is a multisystemic zoonotic infection caused by Borrelia burgdorferi bacteria transmitted by ticks. Lyme disease is a public health problem because of its high incidence in North America and Europe and its increasing presence due to the impacts of climate change on vector distribution. Novel, effective vaccines to prevent the disease are, therefore, urgently needed.
Sepsis-induced coagulopathy (SIC) is a complication of sepsis tied to high mortality in patients. Anticoagulation using a coagulation factor IIa and Xa dual inhibitor might have the potential to improve the treatment of this severe condition.
New vaccines to control tuberculosis (TB) are urgently needed to fight the global burden of the disease, the increase of resistant strains and the lack of effective vaccines to prevent latent TB infections.
Compared to other forms of prevention, a unique issue for pandemic preparedness is that it is forever unclear what pathogen, exactly, the world needs to be prepared for. There are an estimated 300,000 viruses that infect mammals; add in birds, and the estimate grows to more than half a million. Some of those viruses are much greater threats than others.
National Science & Technology Development Agency (NSTDA) has described cordycepin derivatives acting as viral replication inhibitors reported to be useful for the treatment of viral infections.
Using its proprietary FBDD platform, Blacksmith discovered FG-2101, the prodrug form of FG-960, the first known non-hydroxamate LpxC inhibitor that exerted activity against LpxC at the nanomolar range.
Amenis Bioscience Inc. has identified anthranilic acid derivatives acting as peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) and viral replication inhibitors reported to be useful for the treatment of parasitic and viral infections, obesity, cancer, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), inflammatory bowel disease and pulmonary fibrosis.
RSS
